| budesonide / Generic mfg. |
ChiCTR-IPR-17011390: Clinical study of systemic hormones and inhaled hormones in the acute chronic obstructive pulmonary disease |
|
|
| Not yet recruiting | 4 | 100 | | budesonide ;Methylprednisolone Sodium Succinate | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-financing | chronic obstructive disease | | | | |
| Completed | 4 | 60 | | Budesonide ;Budesonide+Clarithromycin | The first affiliated hospital of Sun Yat-sen University; The first affiliated hospital of Sun Yat-sen University, The first affiliated hospital of Sun Yat-sen University | CRSw/nNP | | | | |
ChiCTR-IPR-16008441: Clinical study on the prevention and treatment of acute altitude sickness by respiratory inhalation drugs |
|
|
| Completed | 4 | 200 | | Budesonide; Ventolin ;Combivent ;physiological salt solution | The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army; The First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army, sicentic fundation of the First Affiliated Hospital of Third Military Medical University of Chinese people's Liberation Army | acute altitude sickness | | | | |
ChiCTR2000031893: Efficacy of three Different Budesonide Treatments in Chinese Preschool Children with Recurrent Wheezing |
|
|
| Completed | 4 | 348 | | initially given inhaled BUD 1 mg once a day, assessed every 4 weeks; if the symptom was well controlled and maintained for 12 weeks, the dose was reduced to 25%-50% of the previous dose until the final dose was 0.25 mg, once a day, maintained to 52 weeks) ;1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness ;0.5 mg twice daily as soon as they contacted allergens or had nasal congestion, a runny nose, cough or any other suspicious respiratory symptoms, continuing until the symptoms were reduced or risk factors were absent for 3 days | The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Science and technology department of jiangxi province | Recurrent Wheezing | | | | |
2018-003381-14: Budesonide compared to prednisolone for the treatment of autoimmunehepatitis - A prospective randomized multicenter study Budesonid jämfört med prednisolon vid behandling av autoimmun hepatit -En prospektiv, randomiserad multicenterstudie |
|
|
| Not yet recruiting | 4 | 150 | Europe | Prednisolon, Various, Tablet, Capsule, hard, Prednisolon, Budesonid | Umeå University Hospital, Regional research councils (ALF) | Autoimmune hepatitis, Autoimmune hepatitis, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002762-12: The prevalence of bile acid diarrhéa and the effect of treatment in patients with microscopic colitis |
|
|
| Not yet recruiting | 4 | 54 | Europe | Entocort, Modified-release capsule, hard, Entocort | Zealand University Hospital, Region Sjællands Sundhedsvidenskabelige Forskningsfond, Tillotts Pharma AG | Microscopic colitisBile acid diarrhea Mikroskopisk colitisGaldesyrediarré, Microscopic colitis is a chronic type of diarrhea with inflammation of the large colon, only seen microscopically. The causes of inflammation is unknown, but bile acids seem to play a role. Mikroskopisk colitis er en kronisk form for diarré med betændelse af tyktarmen, som kun kan ses ved mikroskopi. Årsagerne til betændelsen er ukendte, men galdesyre ser ud til at spille en rolle., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
NCT05444543: Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) |
|
|
| Completed | 4 | 23 | US | Fluticasone Propionate, Budesonide | University Hospitals Cleveland Medical Center | Eosinophilic Esophagitis | 10/23 | 10/23 | | |
NCT06528015: Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 206 | RoW | probiotics combined with enteric-coated budesonide capsule, probiotics placebo combined with enteric-coated budesonide capsules | Gang Xu, China Primary Health Care Foundation | Glomerulonephritis, IGA, Probiotics, Budesonide | 12/26 | 12/28 | | |
IA-GRACE-IgANT, NCT06676384: Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? |
|
|
| Not yet recruiting | 4 | 585 | RoW | Oral prednisolone and SoC, Wysolone® by Pfizer Ltd., Gut-directed budesonide and SoC, IgANEF® by MediART Life Sciences Pvt. Ltd., Mycophenolate mofetil (MMF) and SoC, Mycept® by Panacea Biotec Ltd., Hydroxychloroquine and SoC, Ipca HCQ® by IPCA Laboratories Ltd., Non-steroidal mineralocorticoid receptor antagonist and SoC, SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i), Dapmed® by Medgenix Pharma India Pvt. Ltd. | Christian Medical College, Vellore, India, Medical Research Council, India Alliance | IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis | 08/29 | 08/29 | | |
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients with Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 60 | NA | TARPEYO®, delayed-release budesonide capsules | Calliditas Therapeutics AB, Worldwide Clinical Trials | IgA Nephropathy | 05/26 | 11/27 | | |
ACTRN12621001585819: The effect of Budesonide on the occurrence of deteriorating Illness from Covid-19 in Pregnant patients ( BUDI trial) |
|
|
| Not yet recruiting | 3 | 116 | | | Monash Health, nil | Covid-19 | | | | |
ACTRN12623000340639: Budesonide versus prednisolone after liver transplantation: a phase 3, open label, non-inferiority randomised controlled trial |
|
|
| Recruiting | 3 | 100 | | | Austin Health, Austin Health Medical Research Foundation | Liver transplantation, Allograft rejection | | | | |
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
|
|
| Recruiting | 3 | 7819 | RoW | Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo | Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation | Covid19, SARS-Associated Coronavirus | 06/24 | 07/24 | | |
NCT05509933: Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation |
|
|
| Recruiting | 3 | 110 | US | Budesonide | Henry Ford Health System | Engraftment Syndrome | 01/25 | 12/26 | | |
BETHESDa-CD, NCT06719622: Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum |
|
|
| Enrolling by invitation | 2/3 | 114 | Europe | budesonide, omeprazole (proton pump inhibitor) | Medical University of Warsaw, Jagiellonian University, Poznan University of Medical Sciences | Crohn Disease (CD) | 12/27 | 12/27 | | |
| Not yet recruiting | 2 | 70 | | | University of Newcastle, University of Newcastle
, Falk Pharmaceuticals | Functional Dyspepsia | | | | |
2011-003346-40: Study to assess the efficacy of budesonide in preventing diarrhea caused by treatment with cabazitaxel (CABARESC) |
|
|
| Ongoing | 2 | 250 | Europe | Jevtana, Budesonide, Jevtana, Budesonide, Jevtana, Budesonide | Erasmus MC-Daniël den Hoed, Erasmus MC | metastatic prostate cancer | | | | |
IMPACT, NCT05405387: Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant |
|
|
| Recruiting | 2 | 120 | US | Budesonide EC, Placebo | University of Utah | Multiple Myeloma | 02/25 | 02/27 | | |
BESIDE, NCT05214599: Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) |
|
|
| Withdrawn | 2 | 36 | NA | Budesonide Gel | Bazell Pharma AG | Eosinophilic Esophagitis | 11/24 | 04/25 | | |
ChiCTR-TRC-14004138: Impact of intranasal corticosteroid on endothelial function of children with primary snoring |
|
|
| Recruiting | 1 | 104 | | budesonide 32mcg one spray per nostril once daily vs no treatment (watchful waiting as controls), for four months | Department of Paediatrics, The Chinese University of Hong Kong ; The Chinese University of Hong Kong, Department of Paediatrics | primary snoring | | | | |
ChiCTR-ICR-15007314: Budesonide combined Porcine Fibrin Sealant Kit in preventing esophageal stricture after endoscopic submucosal dissection within near-circumferential section of early esophageal cancer: the controlled clinical trial |
|
|
| Recruiting | N/A | 82 | | Porcine Fibrin Sealant Kit ;triamcinolone | Gastroenterology, Xinqiao Hospital; Xinqiao Hospital, Xinqiao hospital | early esophageal cancer | | | | |
ChiCTR2100044443: Impact of flexible bronchoscope on diagnosis and treatment of laryngeal edema before extubation |
|
|
| Recruiting | N/A | 132 | | underwent flexible bronchoscope and diagnosed laryngeal edema, received intravenous 20 mg methylprednisolone ;underwent flexible bronchoscope and diagnosed laryngeal edema, received epinephrine and budesonide sprayed on laryngeal edema through the bronchoscope | The First Affiliated Hospital of ZheJiang Chinese Medical University, Zhejiang Provincial Hospital of TCM; The First Affiliated Hospital of ZheJiang Chinese Medical University, Zhejiang Provincial Hospital of TCM, Health Commission of Zhejiang Province | Laryngeal Edema | | | | |
NCT04952389: Acupuncture Therapy for COVID-Related Olfactory Loss |
|
|
| Completed | N/A | 30 | US | Acupuncture Therapy, Budesonide, Olfactory Training | Mayo Clinic | Olfactory Dysfunction, COVID-19 | 04/23 | 06/23 | | |
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN |
|
|
| Completed | N/A | 200 | RoW | TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor | Ruijin Hospital | Primary IgA Nephropathy | 09/24 | 09/24 | | |
| Recruiting | N/A | 62 | RoW | budesonide, normal saline | Mansoura University | Stridor, Larynx Edema | 02/25 | 06/25 | | |
NCT06676007: A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy |
|
|
| Not yet recruiting | N/A | 200 | NA | Gd-IgA1 test | Sichuan Provincial People's Hospital | IgA Nephropathy (IgAN), Early Initial Therapy | 12/26 | 06/27 | | |
| Recruiting | N/A | 90 | Europe, RoW | Ulcerative colitis Exclusion Diet, UCED, Partial enteral nutrition (PEN), UC nutritional formula, Nestle, free diet, Oral Budesonide | Wolfson Medical Center | Ulcerative Colitis, Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | 03/26 | 09/26 | | |
ACTRN12621000822886: PLUSS (Preventing Chronic Lung Disease in Extremely Preterm Infants Using Surfactant + Steroid)-HEARTS (Haemodynamic Echocardiogram Assessment after Receiving Therapy with Steroids) in extremely preterm infants |
|
|
| Completed | N/A | 158 | | | Melbourne Children's Trials Centre, National Health and Medical Research Council | Extremely preterm birth, Patent Ductus Arterious | | | | |
